Skip to content
10-Q

Quarterly Report

Oncternal Therapeutics, Inc.

0000950170-23-041395

← back to feed
Filed
Aug 10, 2023 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q2 2023 · Aug 3, 2023 58.97M sh
Short Term Investments Q2 2023 · Jun 30, 2023 $29.67M
Short Term Investments Q2 2023 · Dec 31, 2022 $26.58M
Cash And Equivalents Q2 2023 · Jun 30, 2023 $15.83M
Cash And Equivalents Q2 2023 · Dec 31, 2022 $37.14M
Current Liabilities Q2 2023 · Jun 30, 2023 $4.83M
Current Liabilities Q2 2023 · Dec 31, 2022 $7.68M
Total Liabilities Q2 2023 · Jun 30, 2023 $5.59M
Total Liabilities Q2 2023 · Dec 31, 2022 $7.68M
Current Assets Q2 2023 · Jun 30, 2023 $50.08M
Current Assets Q2 2023 · Dec 31, 2022 $67.29M
Total Assets Q2 2023 · Jun 30, 2023 $50.77M
Total Assets Q2 2023 · Dec 31, 2022 $68.65M
Shares Diluted Q2 2023 · Jun 30, 2022 50.06M sh
Shares Diluted Q2 2023 · Jun 30, 2022 49.75M sh
Operating Cash Flow Q2 2023 · Jun 30, 2022 −$15.74M
Stockholders Equity Q2 2023 · Jun 30, 2022 $74M
Stockholders Equity Q2 2023 · Mar 31, 2022 $80.19M
Stockholders Equity Q2 2023 · Dec 31, 2021 $88.12M
Eps Diluted Q2 2023 · Jun 30, 2022 −$0.23
Eps Diluted Q2 2023 · Jun 30, 2022 −$0.44
Eps Basic Q2 2023 · Jun 30, 2022 −$0.23
Eps Basic Q2 2023 · Jun 30, 2022 −$0.44
Net Income Q2 2023 · Jun 30, 2022 −$11.74M
Net Income Q2 2023 · Jun 30, 2022 −$21.65M
Operating Income Q2 2023 · Jun 30, 2022 −$11.8M
Operating Income Q2 2023 · Jun 30, 2022 −$21.71M
Revenue Q2 2023 · Jun 30, 2022 $191K
Revenue Q2 2023 · Jun 30, 2022 $937K